Kenneth J. O’Byrne

Research interests

Publications

• Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

  Journal of Clinical Oncology · 2022 · 10.1200/jco.22.01503

• Immune Checkpoint Inhibitors in Cancer Therapy

  Current Oncology · 2022 · 10.3390/curroncol29050247

• First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

  Journal of Thoracic Oncology · 2021 · https://doi.org/10.1016/j.jtho.2021.09.010

• Understanding the tumor microenvironment for effective immunotherapy

  Medicinal Research Reviews · 2020 · 10.1002/med.21765

• Correction: Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature.

  PubMed · 2020 · https://doi.org/10.1371/journal.pone.0233739

• PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance

  Frontiers in Cell and Developmental Biology · 2020 · 10.3389/fcell.2020.564601

• Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1910231

• First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

  Journal of Clinical Oncology · 2019 · 10.1200/jco.18.01042

• Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

  Frontiers in Oncology · 2018 · 10.3389/fonc.2018.00092

• Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1801946

• Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer

  QUT ePrints (Queensland University of Technology) · 2017

• Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdw611

• Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2016.71.7629

• Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(16)30033-x

• First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

  Journal of Thoracic Oncology · 2016 · https://doi.org/10.1016/j.jtho.2015.11.014

• 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer

  Annals of Oncology · 2015 · 10.1093/annonc/mdv187

• Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(14)71173-8

• Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

  Annals of Oncology · 2014 · https://doi.org/10.1093/annonc/mdu145

• Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

  Annals of Oncology · 2014 · https://doi.org/10.1093/annonc/mdu145

• 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

  Annals of Oncology · 2014 · https://doi.org/10.1093/annonc/mdu123

• 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

  Annals of Oncology · 2014 · https://doi.org/10.1093/annonc/mdu089

• Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1214886

• Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.46.1764

• Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.44.2806

• LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2012.30.15_suppl.lba7500

• Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study

  The Lancet Oncology · 2011 · https://doi.org/10.1016/s1470-2045(11)70149-8

• EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

  The Lancet Oncology · 2011 · 10.1016/s1470-2045(11)70318-7

• Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study

  The Lancet Oncology · 2011 · https://doi.org/10.1016/s1470-2045(11)70149-8

• Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

  The Lancet · 2009 · https://doi.org/10.1016/s0140-6736(09)60569-9

• An Evaluation of Tumor Oxygenation and Gene Expression in Patients with Early Stage Non–Small Cell Lung Cancers

  Clinical Cancer Research · 2006 · https://doi.org/10.1158/1078-0432.ccr-05-2049

• Macrophage and Mast-Cell Invasion of Tumor Cell Islets Confers a Marked Survival Advantage in Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.01.4910

• Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.04.173

• Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies

  Journal of Clinical Oncology · 2003 · 10.1200/jco.2003.08.092

• Chronic immune activation and inflammation as the cause of malignancy

  British Journal of Cancer · 2001 · 10.1054/bjoc.2001.1943

• Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions.

  PubMed · 1999

Current projects

No projects listed.